After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...